Chronic Lymphocytic Leukemia / Michael Hallek, Barbara Eichhorst, Daniel Catovsky, editors.
This book summarizes current knowledge on chronic lymphocytic leukemia (CLL), taking into account the most recent research. All aspects are considered, including pathophysiology, clinical presentation, diagnosis, prognosis, treatment, follow-up, and complications and their management. Readers will f...
Saved in:
| Online Access: |
Full Text (via Springer) |
|---|---|
| Other Authors: | , , |
| Format: | eBook |
| Language: | English |
| Published: |
Cham, Switzerland :
Springer,
[2019]
|
| Series: | Hematologic malignancies (Series)
|
| Subjects: |
Table of Contents:
- Intro; Contents; Part I: Pathophysiology; 1: Chronic Lymphocytic Leukemia: Who, How, and Where?; 1.1 Introduction; 1.2 Who; 1.2.1 Genetic Predisposition to CLL; 1.2.2 Monoclonal B-Cell Lymphocytosis; 1.2.3 Cell of Origin; 1.3 How; 1.3.1 Mechanisms of Leukemogenesis; 1.3.2 Genetic Defects; 1.3.3 B-Cell Receptor; 1.4 Where; 1.4.1 Microenvironmental Stimuli; 1.4.2 Cellular Components; 1.5 Conclusions; References; Part II: Diagnostics; 2: Laboratory Diagnosis of Chronic Lymphocytic Leukaemia; 2.1 Introduction; 2.2 Full/Complete Blood Count; 2.3 Morphology; 2.4 Immunophenotype.
- 2.5 CLL Diagnostic Algorithms Based on Immunophenotype 2.5.1 CLL Scoring Systems; 2.5.2 ERIC/ESCCA Approach to Improving Diagnostic Reproducibility; 2.6 Molecular Diagnostics; 2.6.1 Chromosomal Deletions and Aneuploidy; 2.6.2 Chromosomal Translocations; 2.6.3 The Immunoglobulin Gene; 2.6.4 Other Molecular Abnormalities; 2.7 Differential Diagnosis; 2.7.1 Mantle Cell Lymphoma; 2.7.2 B-Prolymphocytic Leukaemia; 2.7.3 Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma; 2.7.4 Cold Agglutinin Disease (CAD); 2.7.5 Monoclonal B-Cell Lymphocytosis.
- 2.8 Richter's Syndrome/Large Cell Transformation 2.9 Summary; References; Part III: Clinical Presentation; 3: The Clinical Presentation of CLL; 3.1 Introduction; 3.2 Demographics; 3.2.1 Incidence; 3.2.2 Age Distribution; 3.2.3 Gender; 3.3 Clinical Features; 3.3.1 Presentation; 3.3.2 Lymphoid Involvement; 3.3.3 Extramedullary Features; 3.3.4 Constitutional Symptoms; 3.3.5 Second Malignancies; 3.4 Laboratory Investigations; 3.4.1 Full Blood Count; 3.4.2 Other Blood Tests; 3.4.3 Bone Marrow (BM) Examination; 3.4.4 Imaging Tests; 3.4.5 Cytogenetics/Molecular Investigations.
- 4.3.9.1 Recurrent Acquired Single Nucleotide Variants (SNV) in CLLNOTCH1; SF3B1; 4.3.9.2 Hierarchical Model Integrating Prognostic Information from Genomic Studies; 4.3.9.3 Predicting the Risk of High-Grade Transformation; 4.4 Prognostic Markers in the Era of Novel Therapies; 4.5 Outlook; References; Part V: Treatment; 5: Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of Chronic Lymphocytic Leukemia: The 2018 Update; 5.1 Introduction.
- 3.5 Clinical Staging 3.6 The Patient's Perspective; References; Part IV: Prognostic Markers; 4: Prognostic Markers; 4.1 Introduction; 4.2 Clinical Prognostic Markers; 4.2.1 Clinical Staging Systems; 4.2.2 Clinical Prognostic Scores; 4.3 Biological Prognostic Markers; 4.3.1 The Immunoglobulin Locus; 4.3.2 β2-Microglobulin; 4.3.3 Genetic Prognostic Markers; 4.3.4 Copy Number Aberrations; 4.3.5 Deletions of chromosome 13q14.1; 4.3.6 Deletions of 11q22.3 and ATM Inactivation; 4.3.7 Trisomy 12; 4.3.8 Del(17p) and TP53 Inactivation; 4.3.9 Complex Karyotype.